fabomotizole fabomotizole fabomotizole (inn; brand name afobazole) is an anxiolytic drug launched in russia in the early 2000s. it produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. its mechanism of action remains poorly defined however, with gabaergic, ngf- and bdnf-release-promoting, mt1 receptor agonism, mt3 receptor antagonism, and sigma agonism suggested as potential mechanisms. fabomotizole was shown to inhibit mao-a reversibly and there might be also some involvement with serotonin receptors. clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. fabomotizoleclinical datatrade namesafobazoleother namesobenoxazineroutes ofadministrationorallegal statuslegal status us: unscheduled not fda approved pharmacokinetic databioavailability43.64%, pronounced first-pass effectmetabolismextensive hepaticonset of action0.85±0.13 hourselimination half-life0.82±0.54 hoursidentifiers iupac name 4-ethyl]morpholine cas number173352-21-1pubchem cid9862937drugbankdb13623chemspider8038633unii0f8k1x115ckeggd10561chebichebi:135309chemblchembl3707307comptox dashboard (epa)dtxsid00169606 chemical and physical dataformulac15h21n3o2smolar mass307.41 g·mol−13d model (jsmol)interactive image smiles ccoc3ccc2nc(sccn1ccocc1)c2c3 inchi inchi=1s/c15h21n3o2s/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11h,2,5-10h2,1h3,(h,16,17) ykey:wwnucvsrrudypp-uhfffaoysa-n y ny (what is this?) (verify) afobazole from russia experiments of mice have shown antimutagenic and antiteratogenic properties. fabomotizole has found little clinical use outside russia and has not been evaluated by the fda.